Novo Nordisk A/S vs Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) — how do they compare? Novo Nordisk A/S trades at $38.58 (market cap $169.08B), while Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) trades at $58.55 (market cap $11.58B). The key difference: Novo Nordisk A/S is far larger — about 14.6× Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value)'s market cap, and Novo Nordisk A/S pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares USD1.00 par value) for 0 Days on average.
| NVO | TX | |
|---|---|---|
Market Cap | $169.08B | $11.58B |
Volume | 9,259,152 | 456,367 |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $58.99 |
52-Week Low | $35.29 | $35.26 |
Typical Hold Time | 116 Days | 0 Days |
Enterprise Value | $183.28B | $11.90B |
Dividend Yield | 4.72% | 3.73% |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.12, down 1.19% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.96, beating expectations by 17%, continuing a trend of earnings outperformance. Valuation metrics remain attractive with P/E of 9.67 and ROE of 59.82%, while recent news highlights pipeline expansion through $4 billion in licensing deals and progress on oral Wegovy formulations.
The stock presents a compelling value opportunity with strong profitability and growth prospects in obesity/diabetes markets, though technical weakness and competitive pressure from Eli Lilly create near-term headwinds. Analyst consensus remains bullish with $42.33 price target representing 11% upside potential from current levels.
Ternium (TX) trades at $58.99, up 1.81% with strong Q2 2026 earnings beating estimates by 43%. The stock shows solid fundamentals with attractive valuation metrics including P/E of 16.39 and P/S of 0.72. Recent analyst upgrades to Strong Buy highlight improving sentiment as Mexico's steel recovery drives operational momentum and the $4B Pesqueria project promises future capacity growth.
The stock offers value with 7% dividend yield projections and 14.5% upside to $65.52 fair value. Key risks include steel price volatility and trade uncertainty, but declining CapEx should boost free cash flow above 15% yield. Analyst consensus at $57.17 with 50% Buy ratings supports cautious optimism for continued recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Ternium S.A. is a Luxembourg-headquartered steel producer operating an integrated production system, from mining through finished flat and long steel products. It runs 18 production plants and two mining operations across Argentina, Brazil, Colombia, Guatemala, Mexico, and US, serving the automotive, construction, appliance, and energy industries.
Read more on TX →